Scarica l'app Stockscreener
1.10
0.00%
0.00
Pre-mercato:
1.10
Precedente Chiudi:
$1.10
Aprire:
$1.1
Volume 24 ore:
162.36K
Relative Volume:
0.90
Capitalizzazione di mercato:
$25.19M
Reddito:
$950.10K
Utile/perdita netta:
$-16.69M
Rapporto P/E:
-1.1458
EPS:
-0.96
Flusso di cassa netto:
$-15.16M
1 W Prestazione:
-0.90%
1M Prestazione:
-1.79%
6M Prestazione:
-3.51%
1 anno Prestazione:
+12.82%
Intervallo 1D:
$1.06
$1.10
Intervallo di 1 settimana:
$1.05
$1.17
Portata 52W:
$0.734
$2.40
Femasys Inc Stock (FEMY) Company Profile
Nome
Femasys Inc
Settore
Industria
Telefono
770-500-3910
Indirizzo
3950 JOHNS CREEK COURT, SUWANEE
Confronta FEMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
1.10 | 25.19M | 950.10K | -16.69M | -15.16M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
521.96 | 185.91B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
226.87 | 65.59B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
84.89 | 41.99B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
228.69 | 33.57B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
327.56 | 23.72B | 2.88B | 499.60M | 321.60M | 6.74 |
Femasys Inc Borsa (FEMY) Ultime notizie
HPV Testing & Pap Test Market 2025-2032: Scope, Trend, Expansion Strategies with SWOT Analysis - WICZ
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024 - Marketscreener.com
Femasys (NASDAQ:FEMY) Earns “Buy” Rating from HC Wainwright - Defense World
Femasys shares hold price target with buy rating on HRC Fertility deal - Investing.com Nigeria
Intratubal Insemination Device Shown Effective, Safe - Streetwise Reports
Femasys Announces Partnership with HRC Fertility, Esteemed - GlobeNewswire
Femasys Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
The Latest Analyst Ratings For Femasys - Benzinga
Femasys Announces Peer-Reviewed Publication of Positive - GlobeNewswire
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment - Yahoo Canada Finance
Femasys price target lowered to $8 from $10 at Chardan - MSN
Femasys Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Femasys Inc. (FEMY) Quarterly 10-Q Report - Quartzy
Femasys earnings missed by $0.04, revenue fell short of estimates - Investing.com Canada
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates - MSN
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update - The Manila Times
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides - The Bakersfield Californian
Femasys Sales Surge 127% as Boston IVF Partnership, FDA Clearance Fuel Growth | FEMY Stock News - StockTitan
Femasys to Exhibit at the Annual AAGL 2024 Global Conference - GlobeNewswire
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
FEMYFemasys Inc. Latest Stock News & Market Updates - StockTitan
Femasys Partners with Boston IVF to Expand Access to Novel Fertility Treatment - Femtech Insider
Femasys secures new patent for FemBloc birth control By Investing.com - Investing.com South Africa
Femasys issued U.S. patent covering FemBloc device - MSN
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control - GlobeNewswire
Femasys secures new patent for FemBloc birth control - Investing.com
The 10 Best Booths from ASRM 2022 - Exhibitor Online
Femasys Issued New U.S. Patent for FemBloc Permanent Birth Control - MPO-mag
Femasys (NASDAQ:FEMY) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed - GlobeNewswire
Femasys Advances in Women’s Health Innovation - TipRanks
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program - GlobeNewswire
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Femasys Receives Second Order from Spain Partners After - GlobeNewswire
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments - StockTitan
Femasys announes infertility clinic customers from coast to coast - TipRanks
Femasys Announces Infertility Clinic Customers from Coast to Coast - GlobeNewswire
H.C. Wainwright maintains Buy rating on Femasys on secureing strategic Spain distribution - Investing.com India
Femasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Femasys secures distribution partnerships for commercialization of FemaSeed - TipRanks
Femasys Secures Strategic Distribution Partnerships for - GlobeNewswire
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market - StockTitan
Femasys Inc Azioni (FEMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
1.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):